Chemotherapy versus chemoimmunotherapy of head and neck cancer: report of a randomized study.
Thirty-four patients with recurrent squamous cell carcinoma of the head and neck were randomized to receive the five-drug chemotherapy regimen BACON (bleomycin, adriamycin, CCNU, vincristine [Oncovin], and mechlorethamine [nitrogen mustard]; 14 patients) or the same regimen plus bacillus Calmette-Gu erin (BCG) by scarification (20 patients). The majority of both patient groups had received prior surgery and radiation. The patients treated with BACON plus BCG experienced a significantly longer survival (P = 0.014) than those treated with BACON alone. There were five drug-related deaths, and eight other patients required hospitalization for treatment of drug-related morbidity.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001500:BCG Vaccine / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000276:immunology / Q000628:therapy; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D006801:Humans; D008130:Lomustine / Q000627:therapeutic use; D008297:Male; D008466:Mechlorethamine / Q000627:therapeutic use; D008875:Middle Aged; D012075:Remission, Spontaneous; D012189:Retrospective Studies; D013781:Texas; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001500:BCG Vaccine; D001761:Bleomycin; D008466:Mechlorethamine; D014750:Vincristine; D008130:Lomustine; D004317:Doxorubicin